Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 16/20 | 0.74 |
| ▸ | CCND1 | P24385 | 16/20 | 0.74 |
| ▸ | CDK11A | Q9UQ88 | 16/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.74 |
| ▸ | CDK9 | P50750 | 15/20 | 0.74 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.74 |
| ▸ | LTK | P29376 | 1/20 | 0.68 |
| ▸ | CLK2 | P49760 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | CDK7 | P50613 | 1/20 | 0.68 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.68 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.68 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725481 | 0.91 | CDK4 (0.62) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5725366 | 0.86 | CDK4 (0.57) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5742380 | 0.84 | CDK4 (0.85) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5724794 | 0.83 | CDK4 (0.70) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5743604 | 0.83 | CDK4 (0.83) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5744356 | 0.83 | CDK4 (0.83) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5727304 | 0.82 | CDK4 (0.72) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5743145 | 0.82 | CDK4 (0.81) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5741881 | 0.82 | CDK4 (0.80) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5726348 | 0.81 | CCNT1 (0.50) | CDK4CCND1CDK11ACCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | CDK4 2/4885CCND1 28/4885CDK11A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.